Meformin, plasma glucose and free fatty acids in type II diabetic out- patients: Results of a clinical study

Diabetes Research and Clinical Practice

Volumn 37, Issue 1, 1997, Pages 21-33

  Gregorio, F ^a   Ambrosi, F ^b   Manfrini, S ^c   Santucci, A ^b   Filipponi, P ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Anti Diabetic Unit   (Italy)

Author keywords

Anti diabetic activity; Bed time administration; FFA; Metformin

Indexed keywords

FATTY ACID; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION;

BLOOD GLUCOSE; BODY CONSTITUTION; BODY MASS INDEX; C-PEPTIDE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; GLICLAZIDE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEIN(A); MALE; METFORMIN; MIDDLE AGED; REGRESSION ANALYSIS; SEX CHARACTERISTICS;

EID: 0030789574     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(97)00047-8     Document Type: Article

References (75)

1. R.A. DeFronzo, The triumvirate β-cell, muscle, liver: a collusion responsible for NIDDM, Diabetes 37 (1988) 667-687.
2. G.M. Reaven, The fourth Musketeer: from Alexandre Dumas to Claude Bernard, Diabetologia 38 (1995) 3-13.
3. R.H. Unger, Lipotoxicity in the pathogenesisof obesity-dependent NIDDM. Genetic and clinical implications, Diabetes 44 (1995) 863-870.
4. J.P. Felber, E. Haesler, E. Jéquier, Metabolic origin of insulin resistance in obesity with and without type 2 (non-insulin-dependent) diabetes mellitus, Diabetologia 36 (1993) 1221-1229.
5. P.J. Randle, D.A. Priestman, S. Mistry, A. Halsall, Mechanisms modifying glucose oxidation in diabetes mellitus, Diabetologia 37 (2) (1994) 155-161.
6. P. Björntorp, Fatty acids, hyperinsulinemia and insulin resistance: which comes first?, Curr. Opin. Lipidol. 5 (1994) 166-174.
7. G. Paolisso, P.A. Tataranni, J.E. Foley, C. Bogardus, B.V. Howard, E. Ravussin, A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM, Diabetologia 38 (1995) 1213-1217.
8. M. Castro Cabezas, A.T.W, de Bruin, W.H. de Walk, C.C. Shoulders, H. Jansen, D.W. Erkelens, Impaired fatty acid metabolism in familial combined hyperlipidemia: a mechanism associating hepatic apolipoprotein B overproduction and insulin resistance, J. Clin. Invest. 92 (1993) 160-168.
9. D.G. Carey, A.B. Jenkins, L.V. Campbell, J. Freund, D.J. Chisholm, Abdominal fat and insulin resistance in normal and overweight women, Diabetes 45 (1996) 633-638.
10. J. Girard, Role of free fatty acids in insulin resistance of subjects with non-inulin-dependent diabetes, Diabetes Metab. 21 (1995) 79-88.
11. O. Bosello, M. Zamboni, F. Armellini, T. Todesco, Biological and clinical aspects of regional body fat distribution, Diabetes Nutr. Metab. 6 (1993) 163-171.
12. P. Björntorp, Implications of body fat distributions, Diabetes Care 14 (1991) 1132-1143.
13. P.J. Randle, P.B. Garland, C.N. Hales, E.A. Newsholme, The glucose-fatty acids clycle. Its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus, Lancet I (1963) 785-789.
14. M.R. Taskinen, Strategies for the diagnosis of the metabolic syndrome, Curr. Opin. Lipidol. 4 (1993) 434-443.
15. S. Yamashita, T. Nakamura, I. Shimomura, M. Nishida, S. Yoshida, K. Kotani, K. Kameda-Takemuara, K. Tokunaga, Y. Matsuzawa, Insulin resistance and body fat distribution, Diabetes Care 19 (1996) 287-291.
16. G. Boden, Fatty acids and insulin resistance, Diabetes Care 19 (1996) 394-395.
17. F. Gregorio, F. Santeusanio, Le biguanidi: aspetti farmacologici ed impiego clinico, G. Ital. Diabetol. 13 (1993) 43-60.
18. C.J. Dunn, D.H. Peters, Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus, Drugs 49 (5) (1995) 721-749.
19. L. Groop, E. Widén, A. Franssila-Kallunki, A. Ekstrand, C. Saloranta, C. Schalin, J. Eriksson, Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus, Diabetologia 32 (1989) 599-605.
20. M.S. Wu, P. Johnston, W.H.H. Sheu, C.B. Hollenbeck, C.Y. Jeng, I.D. Goldfine, Y.D.I. Chen, G.M. Reaven, Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients, Diabetes Care 13 (1990) 1-8.
21. L. Groop, E. Widen, Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?, Diabetes Metab. 17 (1991) 218-223.
22. C.B. Hollenbeck, P. Johnston, B.B. Varasteh, Y-.D.I. Chen, G.M. Reaven, Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria, Diabetes Metab. 17 (1991) 483-489.
23. A. Riccio, S. Del Prato, S. Virgili DeKreutzenberg, A. Tiengo, Glucose and lipid metabolism in non-insulin-dependent diabetes: effect of metformin, Diabetes Metab. 17 (1991) 180-184.
24. R.A. DeFronzo, N. Barzilai, D.C. Simonson, Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects, J. Clin. Endocrinol. Metab. 73 (1991) 1294-1301.
25. G. Reaven, P. Johnston, C. Hollenbeck, R. Skowroski, J. Zhang, I. Goldfine, Y. Chen, Combined metformin-sulfonylurea treatment of patients with non-insulin-dependent diabetes mellitus in fair to poor glycemic control, J. Clin. Endocrinol. Metab. 74 (1992) 1024-1026.
26. J. Jeppesen, M.Y. Zhou, Y.D.I. Chen, G.M. Reaven, Effects of metformin on postprandial lipemia in patients with fairy to poorly controlled NIDDM, Diabetes Care 17 (1994) 1093-1099.
27. G. Periello, P. Misericordia, E. Volpi, A. Santucci, C. Santucci, E. Ferranini, M.M. Ventura, F. Santeusanio, P. Brunetti, G. Bolli, Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production, Diabetes 43 (1994) 920-928.
28. P.A. Jansson, H.S. Gudbjörnsdottir, O.K. Andersson, P.N. Lönnroth, The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM, Diabetes Care 19 (1996) 160-164.
29. S. DelPrato, S. Marchetto, A. Pipitone, M. Zanon, S. Virgili de Kreutzenberg, A. Tiengo, Metformin and free fatty acid metabolism, Diabetes Metab. Rev. 11 (1) (1995) S33-S41.
30. C.J. Bailey, M.R.C. Path, R.C. Turner, Metformin, N. Eng. J. Med. 334 (1996) 574-579.
31. A.B. Johnson, J.M. Webster, C.F. Sum, L. Heseltine, M. Argyraki, B.G. Cooper, R. Taylor, The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients, Metabolism 42 (1993) 1217-1222.
32. N. Stumvoll, N. Nurjhan, G. Periello, G. Dailey, J.E. Gerich, Metabolic effects of metformin in non-insulin-dependent diabetes mellitus, N. Engl. J. Med. 333 (1995) 550-554.
33. Z.T. Bloomgarden, Metformin, Diabetes Care 18 (1995) 1078-1080.
34. WHO document, Measuring obesity: classification and description of anthropometric data, Copenhagen: WHO Regional Office for Europe, Nutrition Unit, EUR/ICP/ NUT 125, (1988).
35. K. Van der Kooy, J.C. Seidell, Techniques for the measurement of visceral fat: a practical guide, Int. J. Obesity 17 (1993) 187-196.
36. C. Baynes, A.D. Henderson, V. Anyaoku, W. Richmond, R.S. Helkeles, The influence of regional adiposity on atherogenic risk factors in man and women with type 2 diabetes, Diab. Med. 8 (1991) 458-463.
37. M. Ashwell, T.J. Cole, A.K. Dixon, Obesity: new insight into anthropometric classification of fat distribution shown by computed tomography, Br. Med. J. 290 (1985) 1692-1694.
38. P. Compagnicci, per il 'Gruppo di studio S.I.D.- Marche per la Standardizzazione dell'HbA1c', Proposta per la standardizzazione del dosaggio dell'HbA1c con confronto dei valori ottenuti in laboratori diversi di soggetti normali, 14 370 (1994).
39. F. Gregorio, F. Ambrosi, P. Filipponi, S. Manfrini, I. Testa, P. Fumelli, F. Santeusanio, Metformin and haemostatic variables in type II non-insulin-dependent diabetes mellitus, Diab. Nutr. Metab. 8 (1995) 25-32.
40. F. Gregorio, F. Ambrosi, P. Filipponi, S. Manfrini, I. Testa, Is metformin safe enough for ageing type 2 diabetic patients?, Diabetes Metab. 22 (1996) 43-50.
41. L. Benzi, P. Marchetti, P. Cecchetti, R. Navalesi, Determination of metformin and phenformin in human plasma and urine by reversed-phase high-performance liquid chromatography, J. Chromatogr. 375 (1986) 184-189.
42. K. Godfrey, Statistics in practice. Comparing the means of several groups, N. Engl. J. Med. 313 (1985) 1450-1456.
43. L. Mykkänen, M. Laakso, M. Uusitupa, K. Pyörälä, Prevalence of diabetes and impaired glucose tolerance in elderly subjects and their association with obesity and family history of diabetes, Diabetes Care 13 (1990) 1099-1105.
44. E. Bonora, Obesità e distribuzione regionale del tessuto adiposo nel diabete mellito tipo 2, in: O. Vaccaro, E. Bonora, G. Bruno, M.P. Garancini, S. Munoni (Eds.), Il Diabete in Italia, Kurtis, Milano, 1996, pp. 31-40.
45. I. Magnusson, L.D. Rothman, L.D. Katz, R.G. Shulman, G.I. Shulman, Increased rate of gluconeogenesis in type II diabetes mellitus: a 13C nuclear magnetic study, J. Clin. Invest. 90 (1992) 1324-1327.
46. A. Consoli, N. Nurjhan, F. Capani, J. Gerich, Predominant role of gluconeogenesis in increased glucose production in NIDDM, Diabetes 38 (1989) 550-557.
47. R. De Fronzo, A.M. Goodman, Multicentric Metformin study group, efficacy of metformin in patients with noninsulin-dependent diabetes mellitus, N. Engl. J. Med. 333 (1995) 541-549.
48. F. Gregorio, P. Filipponi, F. Ambrosi, S. Manfrini, I. Testa, G. Vespasiani, L. Evangelisti, Effetti metabolici della metformina in relazione al grado di sovrappeso (BMI) e alia distribuzione prevalente delladipe (WHR) La Presse Médicale, ed it, 11 (1994) 177-182.
49. P. Arner, T. Pollare, H. Lithell, Different aetiologies of type 2 (non-insulin-dependent) diabeted mellitus in obese and non-obese subjects, Diabetologia 34 (1991) 483-487.
50. R. Bressler, D. Johnson, New pharmacological approaches to therapy of NIDDM, Diabetes Care 15 (1992) 792-805.
51. K. Rebrin, G.L. Steil, L. Getty, R.N. Bergman, Free fatty acid as a link in the regulation of Hepatic glucose output by peripheral insulin, Diabates 44 (1995) 1038-1045.
52. J.R. Williamson, R.A. Kreisberg, P.W. Felts, Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver, Proc. Natl. Acad. Sci. USA 56 (1966) 247-254.
53. G. Boden, F. Jadali, Effects of lipid on basal carbohydrate metabolism in normal men, Diabetes 40 (1991) 686-692.
54. C.G. Fanelli, S. Calderone, L. Epifano, A. De Vincenzo, F. Modarelli, S. Pampanelli, G. Periello, P. De Feo, P. Brunetti, J.E. Gerich, Demostration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans, J. Clin. Invest. 92 (1993) 1617-1622.
55. J. Svedberg, P. Björntorp, U. Smith, P. Lonnroth, Freefatty acid inhibition of insulin binding, degradation and action in isolated rat hepatocytes, Diabetes 39 (1990) 570-574.
56. L. Van Graal, G. Vansant, K. Van Acker, I. De Leeuw, Decreased hepatic insulin extraction in upper body obesity: relationship to unbound androgens and sex hormone binding glubulin, Diab. Res. Clin. Pract. 12 (1991) 99-106.
57. G. Paolisso, A. Gambardella, L. Amato, R. Tortoriello, A. D'Amore, M. Verricchio, E. D'Onofrio, Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects, Diabetologia 38 (1995) 1295-1299.
58. Y.P. Zhou, V. Grill, Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle, J. Clin. Invest. 93 (1994) 870-876.
59. P. Ebeling, V.A. Koivisto, Non-esterified fatty acids regulate lipid and glucose oxidation and glycogen synthesis in healthy man, Diabetologia 37 (1994) 202-209.
60. A.A. Vaag, A. Handberg, P. Skott, E.A. Richter, H. Beck-Nielsen, Glucose-fatty acid cycle operates in humans at the level of both whole body and skeletal muscle during low and high physiological plasma insulin concentrations, Eur. J. Endocrinol. 130 (1994) 70-79.
61. J.P. Felber, E. Haesler, E. Jéquier, Metabolic origin of insulin resistance in obesity with and without type 2 (non-insulin-dependent) diabetes mellitus, Diabetologia 36 (1993) 1221-1229.
62. P.M. Piatti, L.D. Monti, S.N. Davis, M. Conti, M.D. Brown, G. Pozza, K.G.M.M. Alberti, Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients, Diabetologia 39 (1996) 103-112.
63. K.D. Hepp, R. Renner, Insulin action on the adenyl-cyclase system: antagonism to activation by lipolytic hormones, FEBS Lett. 20 (1972) 191-194.
64. S.J. Yeaman, Hormone sensitive lipase: a multipurpose enzyme in lipid metabolism, Biochim. Biophys. Acta 1052 (1990) 128-132.
65. S.R. Sooranna, E.D. Saggerson, Interactions of insulin and adrenaline with glycerol phosphate acylation processes in fat-cells from rats, FEBS Lett. 64 (1976) 36-39.
66. D.G. Johnston, K.G.M.M. Alberti, Hormonal control of ketone body metabolism in the normal and in diabetic state, Clin. Endocrinol. Metab. 11 (1982) 329-361.
67. G. Fanghänel, L. Sanchez-Reyes, C. Trujillo, D. Sotres, J. Espinosa-Campos, Metformins on glucose and lipid metabolism in patients with secondary failure to sulfonylureas, Diabetes Care 19 (1996) 1185-1189.
68. K. Landin, L. Tengborn, U. Smith, Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors, J. Inter. Med. 229 (1991) 181-187.
69. D. Giuliano, N. De Rosa, G. Di Mario, R. Marfella, R. Acampora, R. Buoninconti, F. D'Onofrio, Metformin improves glucose, lipid metabolism and reduces blood pressure in hypertensive, obese women, Diabetes Care 16 (1993) 1387-1390.
70. D. Giugliano, A. Quatraro, G. Consoli, A. Minei, A. Ceriello, N. DeRosa, F. D'Onofrio, Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors, Eur. J. Clin. Pharmacol. 44 (1993) 107-112.
71. P.J. Pentikäinen, E. Voutilainen, A. Aro, M. Uusitupa, I. Penttilä, H. Vapaatalo, Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial, Ann. Med. 22 (1990) 307-312.
72. L.S. Hermann, B. Scherstén, P.O. Bitzén, T. Kjellström, F. Lindgärde, A. Melander, Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations, Diabetes Care 17 (1994) 1100-1109.
73. P. Vague, I. Juhan-Vague, M.C. Alessi, C. Badier, J. Valadier, Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and trygliceride levels in non-diabetic obese subjects, Thromb. Haemost. 5 (1987) 326-328.
74. F. Gregorio, F. Ambrosi, E. Capodicasa, S. Manfrini, I. Testa, P. Filipponi, Metformin-sulfonylurea combination therapy: the influence of regional adiposity on the biguanide induced haemostatic improvement. Balance in type II diabetic patients, Ann. Experim. Clin. Med. 2 (1994) 136-145.
75. H.E. Brussaard, J.A. Gevers-Leuven, A. Rennings, C. Kluft, H.M.G. Krans, Possible role of non-esterified fatty acids in hypofibrinolysis in type 2 diabetes mellitus, Diabetologia 37 (1) (1994) 14.